Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.
Future Oncol
; 20(10): 623-634, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38230990
ABSTRACT
Aim:
To assess treatment patterns, healthcare resource utilization (HCRU), and costs for patients with diffuse large B-cell lymphoma (DLBCL) who did not receive stem cell transplantation in second-line. Patients &methods:
An administrative MarketScan® database study to assess DLBCL claims from 01/01/2009-30/09/2020.Results:
Most patients (n = 750) received rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in first-line (86.8%) and rituximab (39.5%) or bendamustine ± rituximab ± other (16.3%) in second-line. Over half were hospitalized (mean duration 16.5 (standard deviation [SD] 25.8) days per patient per year). Mean medical/pharmacy costs were US$141,532 per patient per year (SD $189,579), driven by DLBCL-related claims.Conclusion:
Healthcare resource utilization and costs for DLBCL-related claims were due to hospitalizations and outpatient visits. Novel therapies to reduce clinical and economic burdens are needed.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma Difuso de Grandes Células B
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article